PARP as a novel therapeutic target in cancer

Por Annunziata, Christina M., O’Shaughnessy, Joyce
Publicado em 2010

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer

Por Annunziata, Christina M, Bates, Susan E
Publicado em 2010

Editorial: Inhibiting PARP as a Strategic Target in Cancer

Por Zorn, Kristin K., Annunziata, Christina M.
Publicado no Front Oncol (2016)

Targeting the Proteasome With Bortezomib in Multiple Myeloma: Update on Therapeutic Benefit as an Upfront Single Agent, Induction Regimen for Stem-Cell Transplantation and as Maint...

Por Driscoll, James J., Burris, Jason, Annunziata, Christina M.
Publicado em 2012

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Por House, Carrie D., Hernandez, Lidia, Annunziata, Christina M.
Publicado no J Vis Exp (2015)

Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells

Por Kim, Marianne K, James, Jana, Annunziata, Christina M
Publicado no BMC Cancer (2015)

Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment

Por Zeligs, Kristen P., Neuman, Monica K., Annunziata, Christina M.
Publicado no Clin Cancer Res (2016)

Monocyte and interferon based therapy for the treatment of ovarian cancer

Por Green, Daniel S., Nunes, Ana T., Annunziata, Christina M., Zoon, Kathryn C.
Publicado no Cytokine Growth Factor Rev (2016)

Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21

Por Kim, Marianne K., Min, Dong J., Wright, George, Goldlust, Ian, Annunziata, Christina M.
Publicado no Oncotarget (2014)

Activation of NF-κB signaling by IKKβ increases aggressiveness of ovarian cancer

Por Hernandez, Lídia, Hsu, Sarah, Davidson, Ben, Birrer, Michael J., Kohn, Elise C., Annunziata, Christina M.
Publicado em 2010

IKKε coordinates invasion and metastasis of ovarian cancer

Por Hsu, Sarah, Kim, Marianne, Hernandez, Lidia, Grajales, Valentina, Noonan, Anne, Anver, Miriam, Davidson, Ben, Annunziata, Christina M.
Publicado em 2012

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer

Por Kim, Marianne K., Caplen, Natasha, Chakka, Sirisha, Hernandez, Lidia, House, Carrie, Pongas, Georgios, Jordan, Elizabeth, Annunziata, Christina M.
Publicado no BMC Cancer (2016)

The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells

Por Sagher, Ethan, Hernandez, Lidia, Heywood, Callee, Pauly, Gary T, Young, Matthew R, Schneider, Joel, Colburn, Nancy H, Annunziata, Christina M
Publicado em 2014

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

Por Annunziata, Christina M., Kohn, Elise C., LoRusso, Patricia, Houston, Nicole D., Coleman, Robert L., Buzoianu, Manuela, Robbie, Gabriel, Lechleider, Robert
Publicado em 2012

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies

Por Hernandez, Lidia, Kim, Marianne K., Lyle, L. Tiffany, Bunch, Kristen P., House, Carrie D., Ning, Franklin, Noonan, Anne M., Annunziata, Christina M.
Publicado no Gynecol Oncol (2016)

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety

Por HAYS, JOHN L., KIM, GEOFF, WALKER, AMANDA, ANNUNZIATA, CHRISTINA M., LEE, JUNG-MIN, SQUIRES, JENNIFER, HOUSTON, NICOLE, STEINBERG, SETH M., KOHN, ELISE C.
Publicado em 2013

NF-κB transcription factors are co-expressed and convey poor outcome in ovarian cancer

Por Annunziata, Christina M., Stavnes, Helene Tuft, Kleinberg, Lilach, Berner, Aasmund, Hernandez, Lidia F., Birrer, Michael J., Steinberg, Seth M., Davidson, Ben, Kohn, Elise C.
Publicado em 2010

VANDETANIB, DESIGNED TO INHBIT VEGFR2 AND EGFR SIGNALLING, HAD NO CLINICAL ACTIVITY AS MONOTHERAPY FOR RECURRENT OVARIAN CANCER AND NO DETECTABLE MODULATION OF VEGFR2

Por Annunziata, Christina M., Walker, Amanda J., Minasian, Lori, Yu, Minshu, Kotz, Herbert, Wood, Bradford J., Calvo, Katherine, Choyke, Peter, Kimm, Daniel, Steinberg, Seth, Kohn, Elise C.
Publicado em 2010

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

Por Annunziata, Christina M., Hernandez, Lidia, Davis, R. Eric, Zingone, Adriana, Lamy, Laurence, Lam, Lloyd T., Hurt, Elaine M., Shaffer, Arthur L., Kuehl, W. Michael, Staudt, Louis M.
Publicado em 2011

Voltage-gated Na(+) Channel Activity Increases Colon Cancer Transcriptional Activity and Invasion Via Persistent MAPK Signaling

Por House, Carrie D., Wang, Bi-Dar, Ceniccola, Kristin, Williams, Russell, Simaan, May, Olender, Jacqueline, Patel, Vyomesh, Baptista-Hon, Daniel T., Annunziata, Christina M., Silvio Gutkind, J., Hales, Tim G., Lee, Norman H.
Publicado no Sci Rep (2015)